Heart failure is by far the most common cause of hospitalization in Western countries, with onerous economic consequences. Cell therapy holds great promise for use in tissue regeneration and is increasingly used in an effort to improve outcomes in cardiac disease. Recently it has been shown that adipose tissue, in addition to committed adipogenic, endothelial progenitor cells and pluripotent vascular progenitor cells, also contains multipotent cell types (adipose-derived stem cells, ADSCs) that, in cell culture conditions, have shown to have an impressive developmental plasticity including the ability to undergo multilineage differentiation and self-renewal. ADSCs express multiple CD marker antigens similar to those observed on MSCs and are also capable of secreting a large number of angiogenesis-related cytokines, including vascular endothelial growth factor, granulocyte/macrophage colony stimulating factor, stromal-derived factor-1α, and hepatocyte growth factor. Adipose tissue can be harvested in large quantities with minimal morbidity in several regions of the body and, on average, 100 ml of human adipose tissue yields about 1 × 10 6 stem cells. Studies conducted in porcine AMI models have shown a significant LV functional improvement, with no report of any potentially fatal arrhythmias. The APOLLO trial, a prospective, double blind, randomized, placebocontrolled trial currently in the recruiting phase, is a "first-in-man" study that explores the safety and feasibility of ADSC transplantation in patients with acute MI. 963 964 MELIGA ET AL.
INTRODUCTION
tal and clinical conditions using various cell types (8) (9) (10) 24, 35, 42) . The characteristics of the ideal cell still remain to be Primary PCI, thanks to enormous improvements in materials and devices, is nowadays considered the gold defined, but it appears clear that, among the cells efficient in the treatment of heart disease, cells that are au-standard for the treatment of AMI and leads to excellent safety and efficacy results. Nevertheless, revasculariza-tologous, nonembryonic, do not require culturing to obtain a therapeutic dose, and can be administered during tion therapies, though able to restore perfusion and contractile function of postinfarct stunned or hibernated the same procedure may be logistically easier to use. Mesenchymal stem cells, referred also to as marrow myocardium, have no effect on necrotic tissue.
Postinfarction myocardial necrosis and subsequent stromal cells (MSCs), have shown to have some of the above-mentioned ideal properties; MSCs in fact are formation of fibrotic scar that replaces viable myocardium leads to depressed systolic function, reduced dia-multipotent adult stem cells that can expand in culture and are able to differentiate into multiple mesenchymal stolic compliance, left ventricular remodeling, and ultimately to congestive heart failure progression, by far the cell phenotypes, including bone, cartilage, and fat. In addition, MSCs are capable of nonmesenchymal pheno-most common cause of hospitalization in Western countries, with onerous economic consequences. typic differentiation into neurons, skeletal muscle progenitor cells, vascular endothelial cells, and cardiomyo-The potential of cell transplantation to repair damaged myocardium and to grow new viable tissue is at-cytes (14, 20, 22, 31, 40, 53, 55) . So far, these cells have been harvested from bone tractive, and has been widely studied in both experimen-marrow, a tissue source that presents multiple limita-tively slight distinctions, the most interesting of which is the reciprocal expression pattern of the very-late-acti-tions, including: a) donor site morbidity limits the amount of marrow that can be obtained (generally vation antigen 4 or VLA-4 (CD49d/CD29) and its cognate receptor vascular cell-adhesion molecule 1 or 40-50 ml) (3, 18) ; b) MSCs represent <0.01% of all nucleated bone marrow cells in healthy volunteers (approx-VCAM-1 (CD106). ADSCs express VLA-4 but not VCAM-1 in the majority of donors, while MSCs usually imately 1 in 25,000 to 1 in 100,000) (4,5); and c) requires extended time in culture to obtain therapeutic cell express VCAM-1 and not VLA-4 (7) . The consequences of these properties are not clear doses by ex vivo cell expansion, rendering treatment in the acute phase of myocardial infarction impractical.
yet, but this observation is fascinating because both these molecules play an important role in the homing Recently it has been shown that adipose tissue, in addition to committed adipogenic, endothelial progeni-and mobilization process of hematopoietic stem cell from bone marrow (44, 48) . tor cells and pluripotent vascular progenitor cells, contains multipotent cells, similar to MSCs (58,59). This
MSCs and ADSCs are also known to secrete a large number of angiogenesis-related cytokines (37) . ADSCs finding has generated major interest because, in contrast to bone marrow, large quantities of adipose tissue can in standard cultures secrete high levels of hepatocyte growth factor (HGF), vascular endothelial growth factor be easily and safely harvested with minimal morbidity, making it an appealing source for cell therapy.
(VEGF), placental growth factor (PlGF), transforming growth factor-β (TGF-β), fibroblast growth factor CELL CHARACTERISTICS (FGF), granulocyte/macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1 (MCP-Adipose tissue has a notable plasticity during life. Although cellular hypertrophy can partially enable in-1), and stromal-derived factor-1α (SDF-1α), suggesting an important role of ADSCs in neovascularization creases in volume, large variations are usually associated with an increase in adipocyte count (cellular (36,37). Clonally derived, multipotent cells from adipose tis-hyperplasia) accompanied by a concomitant expansion and remodeling of the microvasculature supplying these sue display an immunoprivileged behavior (39) . Less than 1% of ADSCs express the cell surface MHC class-cells (1).
The hyperplastic process of the adipose tissue was I, while class-II is almost absent (25) , being therefore poorly recognized by T lymphocytes. Moreover, ADSCs formerly thought to be mediated by a population of unipotent progenitor cells called preadipocytes. These cells have the ability to suppress lymphocyte reaction in a dose-and time-dependent fashion; such immunosup-have been demonstrated to have potential beyond that of the adipocytic lineage, with an impressive develop-pression probably occurs via the production of IL-4, IL-10, and TGF-β, responsible for the inhibition of lympho-mental plasticity (23, 58) , including the ability to undergo multilineage differentiation and self-renewal (49, cyte proliferation (34). These characteristics, together with the easy avail-54,57,59) ( Fig. 1 ). These cells, present within the stromal vascular fraction of adipose tissue, are generally re-ability and the small amount of tissue needed for their isolation, suggest that ADSCs might even have potential ferred to as adipose-derived stem cells (ADSCs).ADSCs are a cell population with properties that are very simi-as immunoprivileged universal donor cells with the prospective possibility to be used also for allogenic trans-lar, though not identical, to those of marrow-derived MSCs (7, 38, 39, 52) .
plantation. Large quantities of subcutaneous adipose tissue can These cells have extensive proliferative capacity and are able to undergo differentiation along both mesenchy-be safely harvested using liposuction in several regions of the body. A typical harvest out of 100-200 ml of mal lineages (adipogenesis, chondrogenesis, osteogenesis) (11, 14, 20, 22, 31, 40, 53, 55) and nonmesenchymal lineages human adipose tissue contains about 5 × 10 7 nucleated cells. After enzymatic digestion, filtration, and centrifu-(endothelial, smooth muscle and neurogenic), confirming the transdifferentiation ability of ADSCs (40, 41) . gation processes, the nonbuoyant stromal cells part from the buoyant adipocytes (29,32,33). The nonbuoyant frac-In culture, these cells have a surface phenotype rather similar to the MSC phenotype (Table 1) : both cell types tion can yield in excess of 1 × 10 6 stem cells (from 100 cc of fat tissue), about 45-fold more than a typical har-express CD117 (stem cell factor receptor), CD105, STRO1, and CD166 (multilineage differentiation mark-vest of bone marrow aspiration (of 40 ml), which normally contains 2.5 × 10 4 MSCs in a mature adult (3, 30) . ers) (6, 19, 26, 43) , CD90, CD54 (ICAM-1), CD44 and CD29 (β1-integrin) (13, 14) , whereas both cell types do
The ADSC-containing fraction can be cultured with different media (e.g., DMEM-F12; EGM-2-MV, α-MEM, not express the endothelial markers CD31, CD34, and the hematopoietic marker CD45 (7, 19) .
etc.) and supplemented with different growth factors (e.g., VEGF, insulin-like growth factor, basic FGF, etc.) However, MSCs and ADSCs have a number of rela- to stimulate expansion and differentiation into dedicated DIFFERENTIATION CAPABILITIES OF ADSCs lineages. Due to the great concentration of ADSCs nor-ADSCs, similarly to MSCs, have the ability to unmally present in an adipose tissue harvest, it is also posdergo differentiation along both mesenchymal (fat, sible to obtain therapeutic cell doses in as little as 1 after bone, cartilage) and nonmesenchymal lineages (endotheliposuction, without further expansion in culture (32,33), lial cells, smooth muscle) (13, 15, 20, 22, 44, 45) , demontherefore avoiding cell alterations often associated with strating that adipose tissue contains pluripotent cells. culturing.
Furthermore, concerning muscle differentiation, evidence shows that ADSCs have the capability to differentiate into contractile cells with either striated muscle (50) . Freshly isolated ADSCs given immediately after re-ture. After 3 weeks of culture, ADSCs morphologically developed into ventricle-like, atrial-like, and pacemaker-perfusion in a porcine AMI model resulted in a 8% LVEF increase compared to controls at 8-week follow-like cells, displaying tight intercellular connections (evidenced by Cx-43) and spontaneous as well as triggered up (p = 0.023) (2). Interestingly, concordant with the functional im-action potentials with beating. Moreover, these differentiated cells expressed the cardiac-specific transcription provement, wall thickness and capillary density were both significantly increased in the border infarct areas factors Nkx2.5, GATA-4, and MEF-2C, the structural cardiac proteins β-myosin heavy chain (MHC), myosin of the treated group, compared to the control group (28) .
In a study recently published by Miyahara and col-light chain-2 ventricular (MLC-2v), myosin light chain-2 atrial (MLC-2a) as well as the atrial natriuretic peptide leagues (29), ADSCs were transplanted directly onto infarcted murine hearts as a monolayered cell sheet. After (ANP), whereas the skeletal marker MyoD and smooth muscle actin were not expressed. Consistent with these transplantation, the engrafted sheet gradually grew to form a thick stratum that included newly formed vessels, results, after 3 weeks of exposure of ADSCs with a permeable cell membrane to rat cardiomyocyte extracts, the undifferentiated cells, and cardiomyocytes. Autologous transplantation of ADSC sheets resulted in a decreased ADSCs expressed cardiomyocyte markers including sarcomeric alpha-actin, desmin, and cardiac troponin I, as LVEDP, improved maximum and minimum dP/dt, increased diastolic wall thickness, increased left ventricu-well as the gap junction protein connexin-43 (Cx-43) and started to beat spontaneously, as observed by Gaus-lar fractional shortening, and decreased diastolic wall stress, compared to dermal fibroblast sheets taken as a tad et al. in 2004 (17) .
control.
In Vivo Studies of ADSC Differentiation
Human Studies of ADSC Differentiation Several groups have so far reported data about the safety and efficacy of ADSCs to regenerate damaged ADSCs have been used successfully in a variety of indications in humans, including bone reconstruction, myocardium in both small (rats) and large animals (pigs). Strem and colleagues (46) in 2005 used intraven-the treatment of Crohn's disease fistulas (15, 16) , osteogenesis imperfecta (21) , and for breast augmentation tricular injections to deliver freshly isolated ADSCs from Rosa 26 mice (expressing the β-galactosidase and reconstruction after partial mastectomy (56) . The APOLLO trial, currently recruiting patients, is the "first-transgene) into syngeneic recipient mice, following myocardial cryoinjury. β-Galactosidase-positive cells in-man" study that explores the safety and feasibility of ADSC transplantation in patients with acute MI. The were found in treated mice together with the expression of MHC, Nkx2.5, and troponin I at 14 days posttrans-APOLLO trial is a prospective, double blind, randomized, placebo-controlled, sequential dose escalation plantation, suggesting that ADSCs have the ability to engraft injured myocardium and express specific cardio-study that will enroll up to 48 patients (4 cohorts of 12 patients each) with acute MI at the Thoraxcenter, Eras-myocyte markers in vivo.
In another study conducted by the same group, syn-mus MC, Rotterdam. Eligible patients are enrolled following primary PCI geneic freshly isolated ADSCs were injected into the LV chamber of 10 female Lewis rats after 60-min occlusion and undergo liposuction and isolation of the adiposederived regenerative cells fraction (ADRCs) using the of the LAD, resulting in significant increases of 5.1% and 7.7% delta in LVEF at 4 and 12 weeks (Fig. 2 ), Celution TM system (Fig. 4) . ADRCs are then injected within 24 h from the primary PCI into the culprit coro-respectively, compared with control rats (saline treated, n = 10). This study also demonstrated significant improve-nary artery. Main safety end points include: major adverse car-ments in both dP/dt max and dP/dt min in the ADSC-treated rats compared to controls (Table 2) (47) . Moreover, in diac or cerebral event (MACCE) rates, serious adverse events (SAEs)/adverse events (AEs) rates and a compos-accordance with the previous study, cell engraftment was demonstrated 7 days after transplantation (Fig. 3) .
ite clinical end point of death, MI, stroke, and rehospitalization for heart failure. Main feasibility end points Delivery of ADSCs by intracoronary infusion into pigs 2 days after an acute MI through a LAD balloon are: absolute LVEF and changes in LVEF from baseline to 6 months, MI size, regional wall thickness and thick-occlusion resulted in a 3% absolute increase in LVEF while the untreated pigs showed a 9% decline at 6-ening in all segments, LV end systolic volume (LV- ESV), LV end diastolic volume (LV-EDV), and change arrhythmias. For instance, loop recorder monitoring in pigs treated with ADRCs (12) did not show an increase in perfusion defect after revascularization to 6 months as measured by contrast enhanced MRI, echocardiogra-in fatal arrhythmic events or sustained arrhythmias (e.g., bradycardia lower than 45/min or tachycardia above phy, and scintigraphy.
Patients will be followed for 36 months and will un-165/min) in the treated animals. Programmed right ventricular stimulation did not show an increase in suscepti-dergo imaging studies (2D/3D echocardiography, LV angiography, MRI, SPECT), functional evaluation (left bility for arrhythmias by ADRC treatment. On the contrary, cycle length was significantly longer in the ADRC ventricular pressure-volume relationship), clinical evaluations, and laboratory testing at 6, 12, and 18 months. group at the beginning of an induced arrhythmia, suggesting rather a reduction in the overall inducibility of SIDE EFFECTS, ADVERSE EVENTS malignant arrhythmias than an increase in susceptibility.
AND POTENTIAL HURDLES
In addition, there have been no reports on arrhythmias in patients who underwent intramyocardial injections of The main issue related to transplanted cells is their potential arrhythmogenicity. Previous reports conducted ADRCs using the NOGA delivery system in patients with chronic myocardial ishemia in the PRECISE trial. using skeletal myoblasts showed an increased rate of arrhythmic events in the treated groups that raised impor-Issues associated with tissue harvest in patients with a recent AMI under high doses of anticoagulants, GP tant interrogatives on the safety of this treatment and that led often to prophylactic AICD implantation (27).
IIb-IIIa inhibitors, and aspirin are a potential concern, owing to the highly developed vascularization of adi-Although limited safety data are available to date, in vivo preliminary animal studies conducted using ADSCs pose tissue and the consequent bleeding risk. However, only a relatively small amount of tissue is required to have not reported an increase in any potentially fatal obtain an effective cell dose, and hemostasis at the site of liposuction can easily be achieved by local pressure. The APOLLO trial, a "first-in-men" study conducted 2005. with ADSCs in AMI patients, will provide fundamental
